Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 6, 2018

Primary Completion Date

July 20, 2018

Study Completion Date

July 20, 2018

Conditions
Amyloidosis
Interventions
DRUG

GSK2315698 (CPHPC)

GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.

DRUG

GSK2398852 (unlabeled anti-SAP mAb)

Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.

DRUG

89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)

89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.

Trial Locations (1)

SE-751 85

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY